INKT · MiNK Therapeutics, Inc. · Analyst Estimates
$9.34
-0.19 (-1.99%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because the completion of anticipated funding is not entirely within our control, we are required to disclose that substantial doubt exists about our ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q.”View the 10-Q filed Nov 12, 2026
Market Cap
$47.95M
Shares
5.13M
Volume · Nov 13
19.03K
Avg daily vol (3M)
14.64K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for MiNK Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-11-14 13:50 UTC · Publication dates shown per estimate · 7 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-2.58
|
-2.45
|
-2.32
|
2
|
-2.53
|
-1.93
|
-1.93
|
-2.46
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
1
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.72
|
-0.72
|
-0.72
|
1
|
-1.57
|
-1.97
|
-2.65
|
-2.86
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
1
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.71
|
-0.67
|
-0.63
|
2
|
-0.67
|
-0.39
|
-0.39
|
-0.66
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
1
|
— | — | — | — | — | — | — | — |
Q ending 2027-03-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
— | — | — | — | — | — | — | — |
Key facts
CIK
1840229
CUSIP
603693201
13F (30d)
32 filings
23 filers
Visit website
Investor relations